PASSAGE BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $11.52 per share for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-09-03
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $10.99, a 668.53% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.43, a 82.17% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.02, a 41.42% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $13.69, a 8.56% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $5.43, a 30.56% decline from fiscal 2023.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $7.82, a 24.88% decline from fiscal 2022.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $10.41, a 34.82% decline from fiscal 2021.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $15.97, a 1465.69% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.52 S-4/A · filed 2026-09-03 | |||
| 2026-03-31 | $10.99 S-4 · filed 2026-07-21 | |||
| 2025-12-31 | $82.56 S-4/A · filed 2026-09-03 | |||
| 2025-09-30 | $48.96 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $51.09 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $1.43 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $5.43 10-K · filed 2025-03-04 | |||
| 2024-09-30 | $5.95 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $6.80 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $8.02 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $7.82 10-K · filed 2024-03-04 | |||
| 2023-09-30 | $8.58 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $12.98 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $13.69 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $10.41 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $11.65 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $12.08 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $12.61 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $15.97 10-K · filed 2022-03-03 | |||
| 2021-09-30 | $14.65 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $14.84 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $24.21 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | $1.02 10-K · filed 2021-03-03 | |||
| 2020-09-30 | $1.02 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $1.02 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | $1.02 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $1.02 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |